Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kia Sepassi

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Molecular Pharmaceutics|September 7, 2025
Canine Mdr1 Knockout MDCK Cells Reliably Estimate Human Small Intestinal Permeability (<i>P</i><sub>eff</sub>) and Fraction Absorbed (<i>f</i><sub>a</sub>)Kristian Beran, Seong Hee Park, An Van den Bergh, et al.
Journal of Pharmaceutical Sciences|April 3, 2008
Formulation and in vivo evaluation of chlorpropham (CIPC) oral formulationsPhilip J Kuehl, Tim Brenner, Parijat K Jain, et al.
Journal of Medicinal Chemistry|August 14, 2020
Design, Synthesis, and Preclinical Evaluation of 3-Methyl-6-(5-thiophenyl)-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-ones as Selective GluN2B Negative Allosteric Modulators for the Treatment of Mood DisordersChrista C Chrovian, Akinola Soyode-Johnson, Brice Stenne, et al.
Journal of Medicinal Chemistry|December 7, 2017
A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical CandidateChrista C Chrovian, Akinola Soyode-Johnson, Alexander A Peterson, et al.
Journal of Medicinal Chemistry|August 23, 2016
Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptorDevin M Swanson, Brad M Savall, Kevin J Coe, et al.
Journal of Medicinal Chemistry|April 16, 2025
Identification of JNJ-61803534, a RORγt Inverse Agonist for the Treatment of PsoriasisOlaf Kinzel, Steven D Goldberg, Maxwell D Cummings, et al.
European Journal of Pharmacology|May 18, 2011
Characterization of 2-(2,6-dichloro-benzyl)-thiazolo[5,4-d]pyrimidin-7-yl]-(4-trifluoromethyl-phenyl)-amine (JNJ-39729209) as a novel TRPV1 antagonistMichael P Maher, Anindya Bhattacharya, Hong Ao, et al.
Molecular Pharmacology|March 5, 2011
Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitorTerrance D Barrett, Heather L Palomino, Theresa I Brondstetter, et al.
Bioorganic & Medicinal Chemistry Letters|June 22, 2010
Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: identification of candidates for clinical developmentMichael A Letavic, Leah Aluisio, John R Atack, et al.
Journal of Medicinal Chemistry|October 31, 2022
Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton's Tyrosine KinaseMark S Tichenor, John J M Wiener, Navin L Rao, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Molecular Pharmaceutics|September 7, 2025
Canine Mdr1 Knockout MDCK Cells Reliably Estimate Human Small Intestinal Permeability (<i>P</i><sub>eff</sub>) and Fraction Absorbed (<i>f</i><sub>a</sub>)Kristian Beran, Seong Hee Park, An Van den Bergh, et al.
Journal of Pharmaceutical Sciences|April 3, 2008
Formulation and in vivo evaluation of chlorpropham (CIPC) oral formulationsPhilip J Kuehl, Tim Brenner, Parijat K Jain, et al.
Journal of Medicinal Chemistry|August 14, 2020
Design, Synthesis, and Preclinical Evaluation of 3-Methyl-6-(5-thiophenyl)-1,3-dihydro-imidazo[4,5-<i>b</i>]pyridin-2-ones as Selective GluN2B Negative Allosteric Modulators for the Treatment of Mood DisordersChrista C Chrovian, Akinola Soyode-Johnson, Brice Stenne, et al.
Journal of Medicinal Chemistry|December 7, 2017
A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical CandidateChrista C Chrovian, Akinola Soyode-Johnson, Alexander A Peterson, et al.
Journal of Medicinal Chemistry|August 23, 2016
Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptorDevin M Swanson, Brad M Savall, Kevin J Coe, et al.
Journal of Medicinal Chemistry|April 16, 2025
Identification of JNJ-61803534, a RORγt Inverse Agonist for the Treatment of PsoriasisOlaf Kinzel, Steven D Goldberg, Maxwell D Cummings, et al.
European Journal of Pharmacology|May 18, 2011
Characterization of 2-(2,6-dichloro-benzyl)-thiazolo[5,4-d]pyrimidin-7-yl]-(4-trifluoromethyl-phenyl)-amine (JNJ-39729209) as a novel TRPV1 antagonistMichael P Maher, Anindya Bhattacharya, Hong Ao, et al.
Molecular Pharmacology|March 5, 2011
Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitorTerrance D Barrett, Heather L Palomino, Theresa I Brondstetter, et al.
Bioorganic & Medicinal Chemistry Letters|June 22, 2010
Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: identification of candidates for clinical developmentMichael A Letavic, Leah Aluisio, John R Atack, et al.
Journal of Medicinal Chemistry|October 31, 2022
Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton's Tyrosine KinaseMark S Tichenor, John J M Wiener, Navin L Rao, et al.
Pageof 2